Posted by Michael Wonder on 07 Jun 2023
PharmaMar and Luye Pharma announce the acceptance of new drug application for lurbinectedin in China
6 June 2023 - PharmaMar and Luye Pharma have announced today that the new drug application submission of lurbinectedin has been accepted by the Centre for Drug Evaluation of the National Medical Products Administration in China for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after receiving platinum-based chemotherapy.
The new drug application is based on data from a single-arm, dose-escalation, and dose-expansion clinical study conducted in China.
